Literature DB >> 6184151

Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs.

G G Chabot, G E Rivard, R L Momparler.   

Abstract

5-Aza-2'-deoxycytidine (5-aza-dCyd) is an effective antileukemic agent. In view of the importance for an antileukemic agent to cross effectively the blood-brain-barrier, we studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of this drug in rabbits and dogs. The 5-aza-dCyd concentrations in biological fluids were determined by bioassay and high-performance liquid chromatography. 5-Aza-dCyd was administered either as an i.v. bolus or as a continuous i.v. infusion following a loading dose. Blood and CSF samples were collected at various time intervals. After an i.v. bolus, the plasma disappearance of 5-aza-dCyd was biphasic with half-lives of 5 and 43 min in rabbits and of 5 and 75 min in dogs. The apparent volume of distribution at steady state was in the order of 800 ml/kg for both species. The total plasma clearance of the drug was 15 ml/min/kg in rabbits and 9 ml/min/kg in dogs. After a 180 min i.v. infusion, 5-aza-dCyd slow disappearance half-lives were of 39 min in rabbits and of 144 min in dogs. The 5-aza-dCyd concentrations attained in the CSF were 27 and 58% of the plateau plasma concentration in rabbits and dogs, respectively. The drug disparition from the CSF followed closely the plasma profile after an i.v. infusion with a somewhat longer half-life. These results showed that 5-aza-dCyd can cross the blood-CSF barrier effectively, producing cytotoxic concentrations in the CSF when given by i.v. infusion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184151

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  DNA methyltransferase contributes to delayed ischemic brain injury.

Authors:  M Endres; A Meisel; D Biniszkiewicz; S Namura; K Prass; K Ruscher; A Lipski; R Jaenisch; M A Moskowitz; U Dirnagl
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Authors:  Marie Morfouace; Anang Shelat; Megan Jacus; Burgess B Freeman; David Turner; Sarah Robinson; Frederique Zindy; Yong-Dong Wang; David Finkelstein; Olivier Ayrault; Laure Bihannic; Stephanie Puget; Xiao-Nan Li; James M Olson; Giles W Robinson; R Kiplin Guy; Clinton F Stewart; Amar Gajjar; Martine F Roussel
Journal:  Cancer Cell       Date:  2014-03-27       Impact factor: 31.743

3.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

Authors:  Joseph M Scandura; Gail J Roboz; Michelle Moh; Ewelina Morawa; Fabienne Brenet; J Robi Bose; Luis Villegas; Usama S Gergis; Sebastian A Mayer; Cindy M Ippoliti; Tania J Curcio; Ellen K Ritchie; Eric J Feldman
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

4.  A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.

Authors:  Lieselot L G Carrette; Chen-Yu Wang; Chunyao Wei; William Press; Weiyuan Ma; Raymond J Kelleher; Jeannie T Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-27       Impact factor: 11.205

5.  Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors.

Authors:  Amanda J Sales; Caroline Biojone; Mateus S Terceti; Francisco S Guimarães; Marcus V M Gomes; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

6.  Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines.

Authors:  Ina Patties; Jutta Jahns; Guido Hildebrandt; Rolf-Dieter Kortmann; Annegret Glasow
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

Review 7.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

Authors:  Steven E McCormack; Erica D Warlick
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

9.  Osteopontin regulates human glioma cell invasiveness and tumor growth in mice.

Authors:  Hsun-Jin Jan; Chin-Cheng Lee; Yung-Luen Shih; Dueng-Yuan Hueng; Hsin-I Ma; Jing-Huei Lai; Hen-Wei Wei; Horng-Mo Lee
Journal:  Neuro Oncol       Date:  2009-12-23       Impact factor: 12.300

Review 10.  Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.

Authors:  Elias Jabbour; Jean-Pierre Issa; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.